Trials / Recruiting
RecruitingNCT06676527
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 39 (estimated)
- Sponsor
- Jinling Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
Detailed description
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted. Vorolanib is a new generation of multi-target kinase inhibitors with a new chemical structure, which can inhibit tumor angiogenesis and growth, and is used in the treatment of various cancers. This multicenter, single-arm, open-labelled observational study is designed to include patients who meet the requirements for using vorolanib as a second-line treatment for renal cell carcinoma. For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
Conditions
- Neoplasms
- Kidney Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Female Urogenital Diseases
- Male Urogenital Diseases
- Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Carcinoma
- Renal Cell Cancer
- Carcinoma, Renal Cell
- Antineoplastic Agents
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Follow-up study of the treated cohort | For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn. |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2024-11-06
- Last updated
- 2025-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06676527. Inclusion in this directory is not an endorsement.